Themis Medicare is a fifty-year-old Indian pharmaceutical company that built its reputation on making difficult-to-copy molecules, starting with fermentation chemistry and then moving decisively into the complex injectables used in operating theatres and intensive care units. It was founded in 1969 as a joint venture in Vapi, Gujarat, and its recurring approach has been to control its own supply chain - making the active ingredients (APIs) for its own finished drugs - while pivoting repeatedly toward higher-value, harder-to-enter segments where its research skills create a barrier for competitors. # Business segments A single integrated pharmaceutical engine, organised around two customer channels - one selling complex injectables directly to hospitals and the other selling branded pills and creams through retail pharmacies - both fed by a common manufacturing and R&D backbone that makes its own active ingredients. ## 1. The hospital business: complex injectables for operating theatres and ICUs **The company is among India's top three in anaesthesia products and uses that hard-won hospital access to sell a widening range of critical-care drugs that few Indian rivals can make.** - **A moat built on relationships and range** - the Indian hospital market is highly fragmented, unlike the West where three or four players control 90% of it, and breaking in requires both a large product portfolio and years of trust-building with key accounts. - **Anaesthesia was the door-opener** - it took seven to eight years to build a national hospital distribution network for anaesthesia products, and the strategy now is to push more drugs through those same corridors. - **Complex injectables keep competitors out** - the company's edge is its expertise in developing injectable drugs that are technically hard to formulate, which creates high entry barriers and lets it focus on higher-margin products. - **First-to-launch moves** - it recently launched REMITHEM®, a critical-care injection it describes as a global market leader in its category, backed by speaker programmes that reached about 200 anaesthesiologists across three cities. - **Expanding the hospital footprint** - growth is coming from signing chain-hospital contracts, reaching nursing homes, and a phased export push into CIS, Latin America and the Gulf, with regulated markets like the EU and US as a five-year ambition. ## 2. The trade business: branded formulations for retail pharmacies **A portfolio of trusted pill and cream brands sold through a pan-India sales force, with a deliberate focus on orthopaedics and gynaecology.** - **Three specialist divisions** - the business is split into Pharma, Ortho and Gynaecology divisions, each concentrating on a handful of key brands and targeting specialist doctors as well as general practitioners. - **Incentivised feet on the street** - the company runs marketing teams with attractive incentive schemes and splits its sales force into squads that focus separately on priority brands and tail brands, aiming to improve brand productivity. - **A transdermal differentiator** - it imports and promotes Lenzetto®, a novel oestrogen spray for menopause symptoms made by Gedeon Richter of Hungary, approved by US and European regulators and sold in 40 countries, promoted by a dedicated task force visiting gynaecologists across India. - **Co-marketing as a growth lever** - the company invests in co-marketing partnerships, treating them as areas with substantial growth potential alongside its own brands. # Manufacturing and R&D: the shared engine **Three plants and a 3%-of-revenue R&D spend supply both customer channels, with the company making its own active ingredients and developing novel drug-delivery systems.** - **Three integrated factories** - a formulations plant in Haridwar can produce 520 million tablets, 36 million ampoules, 12 million vials and 6 million pre-filled syringes annually, while two API plants in Hyderabad and Vapi together have over 300 metric tonnes of annual capacity. - **Backward integration into APIs** - the company makes synthetic APIs like Simvastatin and Ketamine, almost entirely for export, and has developed a new manufacturing process that cut raw-material cost for one key product by Rs. 4,629 per kilogram. - **R&D as a pillar** - the R&D function runs about 20-24 formulation projects and 8 API projects through documentation each year, and has a pipeline of more than 25 novel drug-delivery products in development or validation. - **Contract-manufacturing backup** - the company signed agreements with two dedicated contract manufacturers in Gujarat to support its high-growth institution and export businesses, adding capacity without building new plants. - **Export reach with a natural hedge** - it exports to more than 44 countries, with 25-30% of revenue coming from abroad and only 5-10% of purchases imported, providing a partial natural hedge against currency moves. # Group structure and partners **A web of subsidiaries, an associate and a joint venture extend the company's reach into fermentation, European partnerships and new manufacturing.** - **Wholly owned Indian subsidiaries** - Themis Chemicals Private Limited was the vehicle for a planned slump sale of the API business, while Rx Themis Private Limited was incorporated in September 2023 to manufacture pharmaceutical drugs. - **A fermentation associate** - the company holds a 23% stake in Gujarat Themis Biosyn, a listed firm that makes pharmaceuticals via fermentation; a proposed merger was withdrawn in June 2025 so the associate could focus on its own organic and inorganic expansion. - **The Gedeon Richter joint venture** - Richter Themis Medicare (49% stake) is a partnership with the Hungarian pharmaceutical group, and under a 2025 agreement Themis earns a management fee of USD 440,000 or 3% of the venture's net revenue, whichever is higher, for business development and regulatory support. - **A smoking-cessation bet** - the company partnered with France's NFL Biosciences to develop and commercialise NFL-101, a nicotine-free tobacco-leaf extract, for the Indian market, bearing all clinical-trial costs for a 334-smoker Phase II/III study and paying double-digit royalties on future sales.